UNITED STATES

SECURITIESANDEXCHANGECOMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of  the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 18, 2023

 

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-39070

 

32-0463781

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1000 Skokie Blvd., Suite 350, Wilmette, IL 60091

 

 60091

 (Address of principal executive offices)

 

(Zip Code)

 

(847) 388-0349

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value

 

MNPR

 

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On January 18, 2023, Monopar Therapeutics Inc. issued a press release announcing the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS).

 

The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release Dated January 18, 2023

 

 

2

 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Monopar Therapeutics Inc.
    
Date: January 18, 2023By:/s/ Kim R. Tsuchimoto

 

Name:

Kim R. Tsuchimoto 
 Title:Chief Financial Officer, Secretary and Treasurer 
    

 

 

3